Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...

Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.

Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...

Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations. The INAVO120 trial showed Itovebi significantly improved progression-free ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...

Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2 billion-Swiss-francs luster to the once high-flying portfolio. The drug, ...